71 results about "Antineoplastic chemotherapy" patented technology

The invention discloses a ROS (reactive oxygen species)-response nano drug delivery system which comprises UCNPs (upconversion nanophosphors), carboxylated PEG (polyethylene glycol) connected with UCNPs, a photosensitizer, a ROS-sensitive thioketal linker and an anti-tumor chemotherapeutic drug connected with the thioketal linker, wherein the photosensitizer contains carboxyl, and the excitation spectrum of the photosensitizer is superposed with the upconversion emission spectrum of UCNPs. The invention also discloses a preparation method and application of the ROS-response nano drug delivery system. The ROS-response nano drug delivery system disclosed by the invention can control the drug release temporally and spatially and can perform combination therapy of photodynamics therapy and chemotherapy to eradicate tumor once; and meanwhile, the fluorescence emitted by UCNPs or the light emitted by the photosensitizer can perform fluorescence imaging, and thus, therapy-imaging integration can be realized.

The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

The subject invention discloses compounds, compositions and methods for treatment and prevention of toxicity due to chemotherapeutic agents and antiviral agents. Disclosed are acylated derivatives of non-methylated pyrimidine nucleosides. These compounds are capable of attenuating damage to the hematopoietic system in animals receiving antiviral or antineoplastic chemotherapy.

The present invention relates to the applications of forsythia ester glycoside in preparing a sensitivity-enhancing and toxicity-reducing medicine in resisting tumor chemotherapy or AIDS. The present invention is a medicinal compound prepared by forsythia ester glycoside and pharmaceutical carrier and / or excipient. The prepared medicinal compound is used for enhancing sensitivity and reducing toxicity in resisting tumor chemotherapy or AIDS, which has the advantages of good curing effect, less side effects and increasing the living quality of patients.

The invention provides a 5-fluorouracil drug sensitivity gene chip detection kit, which can be used to parallelly and economically detect genes related to 5-fluorouracil drug sensitivity. The kit comprises an extraction solution, a hybridization buffer solution, a washing liquor, an amplifying solution, Taq enzyme and a gene chip, the amplifying solution contains a primer for amplifying four genes containing mutant sites, and the four genes include a DPD gene containing IVS14 A / G mutant sites, a GSTPi gene containing Ile105Val mutant sites, an MTHFR gene containing C677T mutant sites, and an XRCC1 gene containing Arg399Glu mutant sites. The 5 fluorouracil is a first-line anti-tumor chemotherapeutic drug, and the detection kit can be used for detecting the four gene mutation conditions sensitive to the 5 fluorouracil drug.

A sensitizing synergist of chemicotherapeutic medicine for treating tumor is a liposoluble epigallocatechol gallate (C22H35O11-Ro).

The invention provides application of Gracilariopsis lemaneiformis polysaccharide and an antitumor drug containing Gracilariopsis lemaneiformis polysaccharide. The application refers to application of the Gracilariopsis lemaneiformis polysaccharide as a synergist in antitumor drug preparation. The antitumor drug contains a Gracilariopsis lemaneiformis polysaccharide synergist, antitumor active components and pharmaceutically acceptable excipients. The invention for the first time finds that combined use of seaweed Gracilariopsis lemaneiformis polysaccharide with chemotherapy drugs paclitaxel, fluorouracil, methotrexate, cisplatin and the like can increase the treatment effect of chemotherapy drugs on tumors. The combined use of Gracilariopsis lemaneiformis polysaccharide with chemotherapy drugs can achieve the effect of inhibiting tumor proliferation and activity on a plurality of tumor cells with different tissue origins, including lung cancer, gastric cancer, cervical cancer and the like, the synergistic effect of Gracilariopsis lemaneiformis polysaccharide on chemotherapy drugs is dose-dependent, and in Gracilariopsis lemaneiformis polysaccharide in-vitro cell experiments, the working concentration does not show toxicity, with the characteristics of rich medicine sources, safety and no toxicity, the Gracilariopsis lemaneiformis polysaccharide can be developed into antitumor drugs or preventive health care products used for antitumor chemotherapy drug synergists, and has clinical application prospect.

The invention provides a metformin acidic double salt, which is prepared by the following steps: mixing metformin and H2Y or MHR for reaction; concentrating; adding a weak polar solvent for crystallization; and filtering and drying. The metformin acidic double salt has the characteristics of good stability and improvement on bioavailability, and is converted into metformin in vivo so as to achieve the aim of killing cancer stem cells. The metformin acidic double salt can be used with other anti-tumor chemotherapy medicines to achieve better treatment effect. The structural general formula of the metformin acidic double salt is shown as follows.

The invention discloses hemoside compounds and an application thereof. The structure general formula of the hemoside compounds are as shown in the description, wherein the heavy solid line represents a beta substituent group, the dash line represents an alpha substituent group, the wavy line represents an alpha substituent group or a beta substituent group, and Me is a methyl; X is a hydroxyl or a carbohydrate chain; Z is hydrogen or a hydroxyl; Y and Y1 are independently alkyls with 0-4 carbon atoms; and W and W1 are independently aryl groups or heterocyclic aryl groups. The compounds claimed in the invention have significant effect on enhancing sensitization of anticancer drugs for inhibiting tumor cells with multidrug resistance, and provide new chemotherapeutic sensitizer selection for tumor chemotherapy. These compounds, which are used as active components, can be used alone, or can be used with anti-tumor chemotherapeutic drugs to realize combined action, and thus to reach the purpose of improving efficacy of anti-tumor chemotherapeutic drugs.

The present invention discloses an application of steroid compounds in preparation of antitumor chemotherapy drug synergists. According to the present invention, pharmacological studies at a cell model and nude mice model level is performed, and paclitaxel is adopted the representative drug of anticancer drugs, such that it is found that the steroid compounds having a Tenacigenin B chemical structure skeleton have significant in vitro and in vivo anticancer drug synergy effects, and can be adopted as the bulk drugs for developing the cancer chemotherapy drug synergists with characteristics of clear structure and significant treatment effect.

The invention belongs to the field of medicines, and provides a composition used for improving the immune function and a preparation method and application thereof. The active ingredients of the composition are hyaluronic acid or hyalurate and lactobacilli. The composition can improve the organism immune function, the composition is particularly suitable for relieving and treating complications induced by the anti-tumor chemotherapy, and the side effects of chemotherapeutic drugs are reduced.

The invention discloses an unsaturated lactone ingredient and anti-tumor chemotherapy drug composition and medical application thereof. The invention provides unsaturated lactone ingredients extracted from natural plants, on the condition without obvious cytotoxicity dosage, these ingredients are combined with platinum chemotherapy drugs to have a collaborative anti-tumor effect and reverse a drug resistance effect of tumors to the platinum drugs.

The invention discloses a dopamine assembly medicine delivery system and a preparation method thereof. The preparation method comprises the following steps: firstly, by using a covalence assembling method, co-assembling dopamine with a dopamine and aldehyde group cross-linking agent so as to obtain a dopamine and aldehyde group cross-linking agent nano assembly material; and adding a chemotherapydrug and a photodynamic therapy photosensitizer in the preparation process of the nano assembly material, and simultaneously loading two medicine molecules through adaptability packaging properties ofa nano material, so as to obtain the dopamine assembly medicine delivery system with pH response. The preparation method disclosed by the invention is simple and convenient to operate and controllable in height, and the prepared dopamine assembly medicine delivery system has the characteristics of being controllable in constitution, size and morphology, and the like, is capable of simultaneouslytaking treatment effects of cancer chemotherapy and photodynamic therapy into play, and has wide application prospects.

The invention relates to a method for measuring content of 5-fluorouracil in plasma and colorectal cancer cells based on high performance liquid chromatography and belongs to the technical field of liquid chromatography medical analysis. 5-fluorouracil (5-Fu) is a miazines antineoplastic drug widely applied clinically at present; the antineoplastic chemotherapy effect of 5-Fu is related to the concentration of 5-Fu in the cancer cells; other side effects are caused when the drug concentration in the body is ultrahigh. For the purpose of enhancing the drug therapeutic effect and reducing the side effects, the trend of the concentration of 5-Fu in the cancer cells and the drug concentration in human body shall be strictly monitored. The monitoring has significant clinical significance in promotion of drug therapeutic effect, reduction of toxicity and prevention of post-operation transfer. According to the method provided by the invention, 5-Fu in plasma and colorectal cancer cells is extracted in the manner of solid phase extraction, so that the extraction efficiency is increased; the chromatographic condition is optimized; the peak pattern is improved by adding a trifluoroacetic acid and methyl alcohol system into a detected flow phase; the number of theoretical plates is increased and the chromatographic condition is mild; under a selected optimal chromatographic condition, the measurement for 5-Fu is more precise and accurate than the measurement in literature reports.

An antineoplastic medicinal composition used to prepare the medicines for treating breast cancer and leukemia contains the epigallocatechin gallate and mitoxantrone in weight ratio of (1-2000): (1-5).

The invention belongs to the field of biomedicine, and particularly relates to an application of an Hsp90 inhibitor in preparing tumor multi-drug resistance reversal agents. The Hsp90 inhibitor is tetrahydroindazolone, and the compound is used as a novel tumor chemotherapeutic sensitizing agent and potentiator, can improve the sensitivity of multi-drug resistance tumor cells to chemotherapeutics, and enhance the effects of antitumor chemotherapeutics.

The invention discloses novel application of the pure traditional Chinese medicine preparation basil polysaccharide, namely application of basil polysaccharide as antineoplastic chemotherapeutic drug synergist in preparing antineoplastic drugs. The chemotherapeutic drug is cis-platinum, pirarubicin HCI or fluorouracil. As proved by experimental study, basil polysaccharide can enhance the functions of multiple chemotherapeutic drugs in inhibiting proliferation and activity of tumour cells (including lung cancer, laryngocarcinoma, stomach cancer and the like) from different tissue sources; in addition, according to a basil polysaccharide extracorporal cell experiment, the working concentration is free of toxicity, and basil polysaccharide is dose-dependent on the synergism of the chemotherapeutic drugs and has a clinical application prospect.

This invention relates to anticancer therapy and more precisely to the immunological control of cancer.Specifically this invention relates to pharmaceutical compositions incorporating as the active ingredient at least one immuno-stimulating agent with charged or central groups of general formula Iwherein X, Y, A, B, R1 and R2 are as defined in the specification together with a radiotherapy method suitable to fight cancer or together with a known antineoplastic chemotherapeutic agent selected from the group consisting of alkylating agents, anti-metabolic agents, agents acting on tubules and tyrosine Kinase inhibitors in conjunction or admixture with an inert non toxic pharmaceutically acceptable diluent or carrier.This invention also relates to the salts of a compound of general formula I with a mineral or organic base, namely a pharmaceutically-acceptable base.Use for treating cancer conditions within a single container or disposed within distinct container

The invention relates to a nanoscale ultrasound microbubble agent for treating tumors by low-intensity focused ultrasound, which comprises ultrasound microbubbles, anti-tumor chemotherapeutic medicaments coated inside the ultrasound microbubbles and an aqueous medium, wherein the ultrasound microbubbles are made from membrane forming materials and perfluoro-alkyl gases. The therapeutic ultrasound microbubble agent is nanoscale microbubbles at the room temperature, and after being injected into animals or human bodies, the microbubbles can gather in tumor part effectively and form miniature bubbles in vivo gradually; and then tumor tissue is irradiated by appropriate treatment ultrasonic waves (low-intensity focused ultrasound), the microbubbles are cracked to release the medicaments and energy, and the released energy allows tumor cell membranes to perforate to increase the permeability of the membranes and promote the absorption of the anti-tumor medicaments, so the tumors can be treated.

The invention discloses an application of ceritinib in the preparation of a tumor chemotherapy drug sensitizer and an antitumor pharmaceutical composition. The antitumor pharmaceutical composition contains a chemotherapy drug and a sensitizer, wherein the sensitizer is ceritinib. Researches find that the ceritinib can be used as a tumor chemotherapy drug resistance sensitizer and can be combined with the chemotherapy drug in use, so that the drug resistance of tumors to the chemotherapy drug can be overcome, the treatment effect of the chemotherapy drug to drug-resistant tumor cells can be remarkably improved, and new ways and measures are provided for the effective treatment of the tumors.

The invention discloses a drug carrier of a slow-release chemotherapy target preparation in a tumor operation and a preparation method thereof. The interior of the drug carrier outer membrane comprises a chemotherapeutic drug and a targeting liposome, the outer membrane is composed of a reticular high molecular polymer, tumor targeting molecules are coupled to the liposome, and the inner part of the liposome also comprises anti-tumor chemotherapeutic drug components. The drug carrier provided by the invention can effectively and slowly release the chemotherapeutic drug, controls the release ofthe drug active ingredients for a long time, reduces the toxic and side effects of the chemotherapeutic drug, strengthens the anti-tumor effect of the chemotherapeutic drug, can be specifically combined on the surface of tumor cells, can inhibit the metastasis of the tumor cells at the same time, and can be effectively applied to focus administration for treating cancer.

The invention relates to a protein micro / nano sphere carrying an antitumor chemotherapeutic medicine. The composition preferably comprises a housing and a core on the premise that the protein is TNFSF (Tumor Necrosis Factor Superfamily) protein, and the antitumor chemotherapeutic medicine is an indissolvable medicine; the housing is composed of the TNFSF protein and is basically completely closed; the core is placed into the housing and contains the antitumor chemotherapeutic medicine; and the maximum diameter of the housing is less than 500nm. The protein micro / nano sphere carrying the antitumor chemotherapeutic medicine has the beneficial effects that the protein micro / nano sphere which is prepared based on the membrane emulsification technology and can carry an indissolvable antitumor chemotherapeutic medicine is provided; and the invention particularly provides a preparation method of the protein micro / nano sphered of the TNFSF protein and HAS (Human Serum Albumin) protein, represented by TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand).

This invention encompasses an expeditious method and compositions that have been found to show selective cytotoxicity against several different cancer cell lines. for treating a wide variety cancer neoplasms that have tumor microenvironments by administering a stand-alone anti-tumor chemotherapeutic composition or administered as an adjunct with chemotherapy and / or radiotherapy with enhanced tumor site affinity that preferentially elevates the pH at the tumor site to suppress and eliminates the acidic tumor microenvironment, administered as chemosensitizing and / or radiosensitizers enhancing the tumor, suppression, remission and inhibit tumor metastisis. The invention encompasses controlling mechanisms of intracellular and extracellular ionic physiology through the administration of alkali salts for pH modulating and for restoring and enhancing ionic physiology. The compositions are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs), thereby inhibiting angiogenesis, reducing metastatic proliferation, supressing tumor generated induced acidotic pain.

The invention discloses an anti-tumor drug and application of isoniazid in preparation of the anti-tumor drug, and belongs to the technical field of biomedicine. According to the application of the isoniazid in preparation of the anti-tumor drug, the anti-tumor drug is a compound preparation of a chemotherapy drug and an enhancer thereof, and the isoniazid is used as the enhancer of the chemotherapy drug. The compound preparation clears away a path through promoting oxidation of tumor cells and blocking cell active oxygen, so as to improve the level of the active oxygen in the tumor cells, thereby enhancing the ability of the chemotherapy drug to kill the tumor cells. According to the anti-tumor drug and the application of the isoniazid in preparation of the anti-tumor drug, the usage amount of the anti-tumor chemotherapy drug is effectively reduced under the same curative effect, the inhibitory effect on the tumor cells is stronger and selectivity is realized, that is, normal cells are less damaged, and the toxic and side effects of doxorubicin are effectively reduced; a safer and more effective chemotherapy drug administration method is provided; a relatively high popularizationvalue is realized.

The invention provides an establishing method for a rabbit tongue carcinoma model. The method comprises the following steps: establishing rabbit tongue squamous carcinoma cell lines; inoculating the rabbit tongue squamous carcinoma cells under skin of a nude mouse and culturing the nude mouse; taking cultured nude mouse subcutaneous tumor tissue, and inoculating the subcutaneous tumor tissue on a rabbit tongue, to establish a rabbit tongue carcinoma model; based on the rabbit tongue carcinoma model, establishing a high lymph gland metastatic rabbit tongue carcinoma animal model. Establishing a tongue carcinoma animal model with high lymph gland metastatic potential completely re-represents clinical characteristics of tongue carcinoma and lymphatic metastasis biological characteristics, and provides better experimental basis for prevention and treatment of tongue carcinoma. The method can be used for sensitivity evaluation of anti-tumor chemotherapeutics, and can also be used for research of radiotherapy, endocrinotherapy, immunological therapy, molecular targeting treatment, and other new treatment means.

This invention relates to nanomedical technologies, namely to the fabrication of nanocarriers of drugs for antitumor chemotherapy. The technical result of the invention consists of increasing the efficiency of antitumor chemotherapy by increasing the activity of the cell absorption of nanocontainers loaded with an antitumor drug, avoiding of the nanocontainer toxicity for cells due to the use of dispersed boron nitride nanoparticles of 50-300 nm in diameter with a well-developed outer surface. The method of boron nitride nanoparticles fabrication for antitumor drug delivery to tumor cells includes synthesis of spherical boron nitride nanoparticles of 50-300 nm in diameter with a well-developed outer surface by chemical vapor deposition using ammonia reaction gas, argon transport gas and powder mixture composed of amorphous boron and oxidizing reactants.

The present invention relates to an application of Chinese medicinal material forsythia fruit in preparation of anti-tumor chemotherapeutic sensitivity-enhancing and attenuating medicine. It is characterized by that the invented medicine can be made up by using forsythia fruit alcohol extract and medicinal carrier and / or excipient through a certain preparation process.

The invention relates to the field of platinum active ligand complexes, in particular to a naphthalimide-platinum (II) complex, a preparation method thereof and application of the complex in preparation of anti-tumor drugs. The invention provides an efficient, low-toxicity and targeted platinum anti-tumor chemotherapeutic drug. The chemical formula of the complex is I. The preparation method comprises the following steps that 1, a naphthalimide derivative ligand c and dichloro bis(dimethyl sulfoxide)platinum (II) are dissolved in a polar solvent for a coordination reaction; 2, a reaction solution obtained in step 1 is washed and dried to obtain the naphthalimide-platinum (II) complex. The naphthalimide-platinum (II) complex is used for the anti-tumor drugs.